NASDAQ:NTRP - Neurotrope Stock Price, Price Target & More

$8.58 -0.02 (-0.23 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$8.60
Today's Range$8.28 - $8.61
52-Week Range$3.40 - $20.76
Volume13,583 shs
Average Volume33,007 shs
Market Capitalization$68.30 million
P/E Ratio-1.46
Dividend YieldN/A

About Neurotrope (NASDAQ:NTRP)

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate NRV II, LLC. The company was founded in 2012 and is based in New York, New York.

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio10.59%
Quick Ratio10.59%


Trailing P/E Ratio-1.46
Forward P/E Ratio-6.04
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book4.56


EPS (Most Recent Fiscal Year)($5.69)
Net Income$-12,610,000.00
Net MarginsN/A
Return on Equity-85.03%
Return on Assets-77.32%


Outstanding Shares7,900,000

How to Become a New Pot Stock Millionaire

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope (NASDAQ:NTRP) released its quarterly earnings data on Friday, August, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. View Neurotrope's Earnings History.

What price target have analysts set for NTRP?

2 brokerages have issued 1 year target prices for Neurotrope's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Neurotrope's share price to reach $23.00 in the next twelve months. View Analyst Ratings for Neurotrope.

Who are some of Neurotrope's key competitors?

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Daniel L. Alkon M.D., Co-Founder, Pres & Chief Scientific Officer (Age 76)
  • Mr. Robert Weinstein, CFO, Treasurer, Sec. Corp., Exec. VP & Compliance Officer (Age 58)
  • Mr. Charles S. Ramat, Consultant (Age 67)
  • Dr. Charles S. Ryan, CEO & Director (Age 54)
  • Mr. Jeffrey Benison, Director of Corp. Communications

Has Neurotrope been receiving favorable news coverage?

Media coverage about NTRP stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurotrope earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 44.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $8.58.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $68.30 million. The company earns $-12,610,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Neurotrope employs 5 workers across the globe.

How can I contact Neurotrope?

Neurotrope's mailing address is 205 EAST 42ND STREET 17TH FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 973-242-0005 or via email at [email protected]

MarketBeat Community Rating for Neurotrope (NTRP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurotrope (NASDAQ:NTRP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Neurotrope in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 168.07%. The high price target for NTRP is $31.00 and the low price target for NTRP is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$23.00$31.00$31.00
Price Target Upside: 168.07% upside163.46% upside344.76% upside344.76% upside

Neurotrope (NASDAQ:NTRP) Consensus Price Target History

Price Target History for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ:NTRP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018Roth CapitalInitiated CoverageBuy -> Buy$15.00MediumView Rating Details
5/2/2017AegisReiterated RatingBuy$31.00N/AView Rating Details
(Data available from 4/19/2016 forward)


Neurotrope (NASDAQ:NTRP) Earnings History and Estimates Chart

Earnings by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ:NTRP) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.42 EPS
Next Year EPS Consensus Estimate: $-1.68 EPS

Neurotrope (NASDAQ NTRP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.79)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.43)ViewN/AView Earnings Details
11/14/2016Q3 2016($2.56)ViewN/AView Earnings Details
8/15/2016Q2 2016($1.60)ViewN/AView Earnings Details
5/13/2016Q1 2016($1.60)ViewN/AView Earnings Details
3/7/2016Q4 2015($1.92)ViewN/AView Earnings Details
11/13/2015Q3 2015($2.88)($2.56)ViewN/AView Earnings Details
8/14/2015Q2 2015($0.08)($0.11)ViewN/AView Earnings Details
5/14/2015Q1 2015($2.88)($6.39)ViewN/AView Earnings Details
3/26/2015Q4 2014($5.75)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.10)($0.14)ViewN/AView Earnings Details
8/14/2014Q2 2014($2.88)ViewN/AView Earnings Details
5/15/2014Q1 2014($2.56)ViewN/AView Earnings Details
4/15/2014Q4 2013($2.56)ViewN/AView Earnings Details
11/14/2013Q3 2013($6.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Neurotrope (NASDAQ:NTRP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neurotrope (NASDAQ NTRP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.45%
Institutional Ownership Percentage: 13.93%
Insider Trading History for Neurotrope (NASDAQ:NTRP)
Institutional Ownership by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ NTRP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018James GottliebDirectorSell314$8.42$2,643.88View SEC Filing  
12/2/2016Bruce BernsteinDirectorBuy50,000$0.28$14,000.0050,000View SEC Filing  
11/23/2016Kenneth J GorelickDirectorBuy5,000$0.29$1,450.0010,000View SEC Filing  
8/26/2016Kenneth J GorelickDirectorBuy5,000$0.41$2,050.005,000View SEC Filing  
11/23/2015James GottliebDirectorBuy10,000$0.59$5,900.005,000View SEC Filing  
(Data available from 1/1/2013 forward)


Neurotrope (NASDAQ NTRP) News Headlines


SEC Filings

Neurotrope (NASDAQ:NTRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Neurotrope (NASDAQ NTRP) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.